Adjuvant Capital has established a European location in Zurich according to an article on startupticker.ch. The American investment company founded in 2019 supports innovations in the life sciences sector. A range of investors are behind Adjuvant Capital, including the Bill & Melinda Gates Foundation as well as Merck and Novartis, for example.
Adjuvant Capital has already gained an important partner for its Zurich site: Philippe Dro will support the company from Switzerland according to a press release. Dro has been active in the life sciences sector for 25 years. Among other things, he co-founded the biotech company Axovan, which was taken over by Actelion, based in the canton of Basel-Landschaft, in 2003. He was also CEO of the biotech company GlycoVaxyn from Schlieren in the canton of Zurich, which was taken over by GlaxoSmithKline in 2015. He currently sits on the administrative boards of life sciences companies such as Luciole Medical in Zurich and LimmaTech Biologics in Schlieren.
Glenn Rockman, Managing Partner at Adjuvant Capital, is quoted in the press release, saying: “We are excited to welcome someone of Philippe's caliber to the Adjuvant team.” He goes on to add: “With decades of leadership in the life science and medical device industries as a CEO, founder and investor, Philippe will play an important role in expanding Adjuvant's presence and investment activities across Europe.”